… Thus, to assess whether vertical inhibition of the RAS–MAPK pathway could block feedback
reactivation and enhance the efficacy of KRAS G12C inhibition, we evaluated whether …

… MAPK pathway modulation and … KRAS inhibitors as a combination backbone that has the
potential to augment the anti-tumor effect of KRASG12C inhibitors by vertical pathway inhibition…

… vertical targeting). In this review, we discuss strategies of multitarget inhibition with a focus on
vertical signaling pathway … Another mode of acquired resistance to MEK inhibitors in K-Ras …

… with a G12C inhibitor for treatment of KRAS G12C mt solid tumors. … /MEK inhibitor VS-6766
enhances antitumor efficacy of KRAS-G12C inhibitors through a vertical pathway inhibition …

… quickly emerge that limit the benefit of vertical pathway cotargeting, at least in some patients…
combination of KRAS G12C (and BRAF) and SHP2 inhibitors and expect that KRAS G12C …

… , however single agent use of MAPK inhibitors in the clinic is often limited by … Vertical pathway
combination strategies are therefore of interest for addressing resistance through pathway …

… These observations support the RAF-MEK-ERK cascade as the key effector pathway driving
KRAS-dependent PDAC. However, to date, therapeutic targeting of MEK in KRAS mutant …

… transferases, or proteins on downstream effector pathways controlled by RAS. Farnesyl
transferase inhibitors largely failed in clinical trials for KRAS or NRAS mutant cancers due to the …

… efficacy of vertical inhibition of the RAS-pathway by targeting … (PDX) tumors with primary
KRAS mutation. In total, 19 different … Vertical inhibition with trametinib and cetuximab induced SD …

… b, after prolonged inhibition of the MAPK pathway through vertical suppression of EGFR
and MEK, the compensatory upregulation of RTKs and their ligands generates a preferential …